AB928


Catalog No. size PriceQuantity
M7103-2 2mg solid $107
M7103-10 10mg solid $441

Description

Cas:2239273-34-6

Product Information

AB928 is a dual antagonist of the A2aR and A2bR adenosine receptors, leads to greater immune activation and reduced tumor growth when combined with chemotherapy.

 

Chemical Formula: C23H22N8O

 

Exact Mass: 426.1917

 

Molecular Weight: 426.484

 

Elemental Analysis: C, 64.77; H, 5.20; N, 26.27; O, 3.75

 

Synonym:

 

AB928

AB-928

AB 928

 

Chemical Name: 3-[2-Amino-6-[1-[[6-(2-hydroxypropan-2-yl)pyridin-2-yl]methyl]triazol-4-yl]pyrimidin-4-yl]-2-methylbenzonitrile

 

InChi Key:

BUXIAWLTBSXYSW-UHFFFAOYSA-N

 

InChi Code: InChI=1S/C23H22N8O/c1-14-15(11-24)6-4-8-17(14)18-10-19(28-22(25)27-18)20-13-31(30-29-20)12-16-7-5-9-21(26-16)23(2,3)32/h4-10,13,32H,12H2,1-3H3,(H2,25,27,28)

 

Smiles Code:

N#CC1=CC=CC(C2=NC(N)=NC(C3=CN(CC4=NC(C(C)(O)C)=CC=C4)N=N3)=C2)=C1C

 

 

Technical Data:

 

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

 

In Vitro:

In human in vitro cell cultures, moDC differentiated in the presence of adenosine showed a decreased ability to stimulate IFN-γ secretion from allogenic CD4+ T-cells in a MLR. This suppression is significantly reversed by addition of AB928. Multiplexed gene expression profiling using NanoString identified a cassette of 39 genes that are regulated by adenosine during moDC differentiation. AB928 shows rescue of these gene expression changes.

 

In Vivo:

Concurrent treatment with AB928 and chemotherapy results in significantly reduced tumor volume in vivo using AT3-OVA tumors; Similar results are observed for the combination of AB928 and NSC 266046. AB928 is also capable of suppressing growth of B16-F10 tumors both as a single agent or in combination with α-PD-1 therapy. AB928 increases the antitumor immune response leading to suppressed tumor growth and increased immune cell infiltration in mouse syngeneic tumors.

 

 

References

 

  1. Preparation of azolopyrimidine for the treatment of cancer and immune related disorders By Beatty, Joel; Debien, Laurent; Jeffrey, Jenna; Leleti, Manmohan Reddy; Mandal, Debashis; Miles, Dillon; Powers, Jay; Rosen, Brandon; Thomas-Tran, Rhiannon; Sharif, Ehesan. From PCT Int. Appl. (2018), WO 2018136700 A1 20180726.

 

Products are for research use only. Not for human use.

Payment & Security

American Express Diners Club Discover JCB Mastercard PayPal Venmo Visa

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed